Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Strata Critical Medical, Inc.
SRTA
NASDAQ·Industrials·Airlines, Airports & Air Services·Mkt cap $456.9M
$5.41
▲ +2.46%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$3.68 - $6.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 27.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Exclusive focus on time-critical organ transplant logistics with regulatory expertise
- Integrated air and ground network enabling fastest delivery times
- Mission-critical service with high switching costs and recurring revenue model
Bear Case
1 risk
- High volatility (beta 2.2). Larger-than-normal price swings expected.
Growth
Profitability at risk
Increasing organ transplant demand from aging U.S. population
Value
Deep value opportunity - significant discount to Airlines peers
Momentum
Hot
+27.2% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying SRTA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 11, 2026
MAY 6, 2026
Reported EPS of $0.03 vs -$0.04 consensus (+175.0% surprise). Revenue of $67.4M vs $63.7M expected (+5.8%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+175.0%
Next: May 11, 2026
Revenue trend · last 8Q
—
—
+14%
+5%
+4%
-34%
-58%
+24%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$67.9M
$74.9M
$54.4M
$54.3M
$70.8M
$49.3M
$22.7M
$67.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
3.7%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.